Status:
COMPLETED
Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Hamamatsu University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
40-75 years
Phase:
PHASE2
PHASE3
Brief Summary
A comparison of combination chemotherapy of sildenafil plus carboplatin and weekly taxol with carboplatin and weekly taxol in patients with previously untreated advanced non-small cell lung cancer. Th...
Detailed Description
Sildenafil is one of selective phosphodiesterase type 5 inhibitors. It is used to block the degradative action of phosphodiesterase type 5 on cyclic GMP in the smooth muscle cells lining the blood ves...
Eligibility Criteria
Inclusion
- Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer
- Good performance status (ECOG 0-1)
- No previous treatment
- Adequate bone marrow, liver and renal functions
- Must be able to swallow tablets
- Provided written informed consent
Exclusion
- Severe complications or a concomitant malignancy
- Contraindicated sildenafil, carboplatin or taxol
- Inappropriate patients for entry to this study, judged by the physicians
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00752115
Start Date
February 1 2007
End Date
December 1 2010
Last Update
September 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamamatsu University School of Medicine
Hamamatsu, Japan